Drug-tolerant persister cells in acute myeloid leukemia: pressing challenge and promising new strategies for treatment
Authors:
Open Access
- 14 May 2025
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1586552
Abstract
Acute myeloid leukemia (AML) exhibits a pronounced ability to develop drug resistance and undergo disease relapse. Recent research has noticed that resistance to treatments could substantially be attributed to drug-tolerant persister (DTP) cells, which are capable of surviving under therapeutic pressures. These are transient, reversibly dormant cells with the capability to act as a reservoir for disease relapse. DTP cells utilize diverse adaptive strategies to optimize the ecological niche, undergo metabolic reprogramming, and interact with microenvironment. The persister state of AML is established through transient cellular reprogramming, thus allowing cells to survive the initial phase of drug therapy and develop drug resistance. Our review explores the identification and phenotypic characteristics of AML DTP cells, as well as their clinical relevance. We summarize the mechanisms underlying the persistence of AML DTP cells and the molecular attributes that define the DTP state. We further address the current challenges and future prospects of DTP-targeting approaches. Understanding these features may provide critical insights into novel therapeutic strategies aimed at targeting AML DTP cells, especially in the new era of immunotherapy against AML.Keywords
Funding Information
- National Natural Science Foundation of China (No. 82272182)
This publication has 155 references indexed in Scilit:
- Recent progress in chimeric antigen receptor therapy for acute myeloid leukemiaAnnals of Hematology, 2024
- Cancer profiles in China and comparisons with the USA: a comprehensive analysis in the incidence, mortality, survival, staging, and attribution to risk factorsScience China Life Sciences, 2023
- Targeting drug‐tolerant cells: A promising strategy for overcoming acquired drug resistance in cancer cellsMedcomm, 2023
- Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitionersCancer and Metastasis Reviews, 2021
- Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approachCancer, 2021
- An introduction to chimeric antigen receptor (CAR) T‐cell immunotherapy for human cancerAmerican Journal of Hematology, 2019
- Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemiaJournal of Cancer Research and Clinical Oncology, 2018
- Role of Microenvironment in Resistance to Therapy in AMLCurrent Hematologic Malignancy Reports, 2015
- Regulation of reactive oxygen species in stem cells and cancer stem cellsJournal of Cellular Physiology, 2011
- Leukemia stem cellsInternational Journal of Cancer, 2011